UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

IBERE PHARMACEUTICALS

(Name of Issuer)

 

Common Stock, Class A

(Title of Class of Securities)

 

G46843101

(CUSIP Number)

 

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

x Rule 13d-1(b)

 

¨ Rule 13d-1(c)

 

¨ Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. G46843101

 

           
1   NAMES OF REPORTING PERSONS
    MAGNETAR FINANCIAL LLC
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)    ¨
  (b)    ¨
3   SEC USE ONLY
   
   
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  5   SOLE VOTING POWER                   0
     
NUMBER OF    
       
SHARES 6   SHARED VOTING POWER 
BENEFICIALLY   785,872
OWNED BY    
       
EACH 7   SOLE DISPOSITIVE POWER         0
REPORTING    
PERSON    
       
WITH: 8   SHARED DISPOSITIVE POWER
    785,872
     
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  785,872
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  ¨
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  5.69%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IA, OO

 

 

 

 

CUSIP No. G46843101

 

           
1   NAMES OF REPORTING PERSONS
    MAGNETAR CAPITAL PARTNERS LP
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)    ¨
  (b)    ¨
3   SEC USE ONLY
   
   
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  5   SOLE VOTING POWER                   0
     
NUMBER OF    
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY   785,872
OWNED BY    
       
EACH 7   SOLE DISPOSITIVE POWER         0
REPORTING    
PERSON    
       
WITH: 8   SHARED DISPOSITIVE POWER
    785,872
     
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  785,872
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  ¨
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  5.69%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  HC, PN

 

 

 

 

CUSIP No. G46843101

 

           
1   NAMES OF REPORTING PERSONS
    SUPERNOVA MANAGEMENT LLC
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)    ¨
  (b)    ¨
3   SEC USE ONLY
   
   
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  5   SOLE VOTING POWER                   0 
     
NUMBER OF    
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY   785,872
OWNED BY    
       
EACH 7   SOLE DISPOSITIVE POWER         0
REPORTING    
PERSON    
       
WITH: 8   SHARED DISPOSITIVE POWER
    785,872
     
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  785,872
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  ¨
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  5.69%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  HC, OO

 

 

 

 

CUSIP No. G46843101

 

           
1   NAMES OF REPORTING PERSONS
    DAVID J. SNYDERMAN
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)    ¨
  (b)    ¨
3   SEC USE ONLY
   
   
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States of America
       
  5   SOLE VOTING POWER                   0      
     
NUMBER OF    
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY   785,872
OWNED BY    
       
EACH 7   SOLE DISPOSITIVE POWER         0
REPORTING     
PERSON    
       
WITH: 8   SHARED DISPOSITIVE POWER
    785,872
     
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  785,872
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  ¨
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  5.69%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  HC, IN

 

 

 

 

SCHEDULE 13G

 

Item 1(a)Name of Issuer.

 

IBERE PHARMACEUTICALS (the “Issuer”)

 

Item 1(b)Address of Issuer’s Principal Executive Offices.

 

2005 MARKET STREET, SUITE 2030

PHILADELPHIA, PA 19103

 

Item 2(a)Name of Person Filing.

 

This statement is filed on behalf of each of the following person (collectively, the “Reporting Persons”):

 

i)Magnetar Financial LLC (“Magnetar Financial”);
ii)Magnetar Capital Partners LP (Magnetar Capital Partners”);
iii)Supernova Management LLC (“Supernova Management”); and
iv)David J. Snyderman (“Mr. Snyderman”).

 

This statement relates to the Shares (as defined herein) held for Magnetar Constellation Fund II, Ltd (“Constellation Fund II”), Magnetar Constellation Master Fund, Ltd (“Constellation Master Fund”), Magnetar Systematic Multi-Strategy Master Fund Ltd (“Systematic Master Fund”), Magnetar Capital Master Fund Ltd (“Master Fund”) , Magnetar Xing He Master Fund Ltd (“Xing He Master Fund”), Purpose Alternative Credit Fund Ltd ("Purpose Fund"), Magnetar SC Fund Ltd (“SC Fund”), all Cayman Islands exempted companies; Magnetar Structured Credit Fund, LP (“Structured Credit Fund”), a Delaware limited partnership; Magnetar Lake Credit Fund LLC ("Lake Credit Fund"), Purpose Alternative Credit Fund - T LLC ("Purpose Fund - T"), Delaware limited liability companies; collectively (the “Magnetar Funds”). Magnetar Financial serves as the investment adviser to the Magnetar Funds, and as such, Magnetar Financial exercises voting and investment power over the Common Stock held for the Magnetar Funds’ accounts. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Financial. Supernova Management is the general partner of Magnetar Capital Partners. The manager of Supernova Management is Mr. Snyderman.

 

Effective October 24, 2022 Alec N. Litowitz was replaced by David J. Snyderman as Chief Executive Officer of Magnetar Financial and the manager of Supernova Management. Accordingly, Mr. Snyderman is being added as a Reporting Person to this Schedule 13G, and Mr. Litowitz has been removed as a Reporting Person, as Mr. Litowitz is no longer a beneficial owner of any of the shares of Common Stock held by the Magnetar Funds.

 

Item 2(b)Address of Principal Business Office.

 

The address of the principal business office of each of Magnetar Financial, Magnetar Capital Partners, Supernova Management, and Mr. Snyderman is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201.

 

 

 

 

Item 2(c)Place of Organization.

 

i)Magnetar Financial is a Delaware limited liability company;
ii)Magnetar Capital Partners is a Delaware limited partnership;
iii)Supernova Management is a Delaware limited liability company; and
iv)Mr. Snyderman is a citizen of the United States of America.

 

Item 2(d)Title of Class of Securities.

 

Common Stock

 

Item 2(e)CUSIP Number.

 

G46843101

 

Item 3Reporting Person.

 

(e) x An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E)

(g) x A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G)

 

Item 4Ownership.

 

Item 4(a)Amount Beneficially Owned:

 

As of December 31, 2022, each of Magnetar Financial, Magnetar Capital Partners, Supernova Management and Mr. Snyderman held 785,872 Shares. The amount consists of (A) 77,502 Shares held for the account of Constellation Fund II; (B) 269,186 Shares held for the account of Constellation Master Fund; (C) 63,000 Shares held for the account of Systematic Master Fund; (D) 30,882 Shares held for the account of Master Fund; (E) 40,136 Shares held for the account of Lake Credit Fund; (F) 91,342 Shares held for the account of Xing He Master Fund; (G) 38,060 Shares held for the account of Purpose Fund; (H) 60,202 Shares held for the account of SC Fund; (I) 103,106 Shares held for the account of Structured Credit Fund; and (J) 12,456 Shares held of the account of Purpose Fund - T. The Shares held by the Magnetar Funds represent approximately 5.69% of the total number of Shares outstanding (calculated pursuant to Rule 13d-3(d)(1)(i)) of the outstanding shares of the Issuer).

 

Item 4(b)Percent of Class:

 

(i) As of December 31, 2022, each of Reporting Persons were deemed to be the beneficial owner constituting approximately 5.69% of the total number of Shares outstanding (based upon the information provided by the Issuer in its Form 10-Q filed with the SEC on November 14, 2022, there were approximately 13,800,000 Shares outstanding as of November 14, 2022).

 

 

 

 

Item 4(c)Number of Shares of which such person has:

 

Magnetar Financial, Magnetar Capital Partners, Supernova Management, and Mr. Snyderman:

 

(i)Sole power to vote or to direct the vote: 0
(ii)Shared power to vote or to direct the vote : 785,872
(iii)Sole power to dispose or to direct the disposition of: 0
(iv)Shared power to dispose or to direct the disposition of: 785,872

 

Item 5Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

 

Item 6Ownership of More Than Five Percent on Behalf of Another Person.

 

This Item 6 is not applicable.

 

Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

 

This Item 7 is not applicable.

 

Item 8Identification and Classification of Members of the Group.

 

This Item 8 is not applicable.

 

Item 9Notice of Dissolution of Group.

 

This Item 9 is not applicable.

 

Item 10Certification.

 

By signing below the Reporting Persons certifies that, to the best of their knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

SIGNATURE 

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 2, 2023 magnetar financial llc
   
  By: Magnetar Capital Partners LP, its Sole Member
  By: Supernova Management LLC, its General Partner
   
  By: /s/ Hayley A. Stein
  Name:     Hayley A. Stein
  Title:       Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC
 
Date: February 2, 2023 magnetar capital partners LP
   
  By:     Supernova Management LLC, its General Partner
   
  By: /s/ Hayley A. Stein
  Name:    Hayley A. Stein
  Title:      Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC
   
Date: February 2, 2023 supernova management llc
   
  By: /s/ Hayley A. Stein
  Name:      Hayley A. Stein
  Title:        Attorney-in-fact for David J. Snyderman, Manager
   
Date: February 2, 2023 DAVID J. SNYDERMAN
   
  By: /s/ Hayley A. Stein
  Name:     Hayley A. Stein
  Title:       Attorney-in-fact for David J. Snyderman

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Joint Filing Agreement, dated as of February 2, 2023, among the Reporting Persons.
99.2   Power of Attorney, dated as of December 22, 2022 (incorporated by reference to Exhibit 99.2 to the Schedule 13G filed by the Reporting Persons on February 2, 2023)

 

 

 

Ibere Pharmaceuticals (NYSE:IBER)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Ibere Pharmaceuticals.
Ibere Pharmaceuticals (NYSE:IBER)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Ibere Pharmaceuticals.